Search

Search Results

• 

  Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients

  S. Canestri, M.C. Totaro, E. Serone, B. Tolusso, D. Frezza, E. Gremese, G. Ferraccioli

  368-373

  20-12-2012

  Published: 20 December 2012

  1964

  PDF: 754
• 

  Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents

  S.L. Bello, L. Serafino, C. Bonali, N. Terlizzi, C. Fanizza, C. Anecchino, G. Lapaldula

  299-306

  11-12-2012

  Published: 11 December 2012

  2096

  PDF: 1157
• 

  Safety of rituximab in the routine treatment of rheumatoid arthritis in Italy in patients refractory to anti-TNFa drugs: results from the observational retrospective-prospective RUBINO study

  L. Bazzichi, D. Biasi, E. Tinazzi, M. Muratore, R. Pellerito, R. Russo, M. Corsaro Santi, P. De Sandre, O. Epis, M. Granata, B. Kroegler, C. Meschini, F. Versace, C. Astolfi

  224-232

  06-11-2014

  Published: 6 November 2014

  2122

  PDF: 1506
• 

  Granulomatosis polyangiitis associated with meningeal involvement: response to rituximab therapy after failure of cyclophosphamide

  M. Benucci, F. Li Gobbi, P. Panconesi, M. Manfredi, P. Sarzi-Puttini, F. Atzeni

  90-94

  27-05-2013

  Published: 27 May 2013

  2387

  PDF: 836
• 

  Successful treatment of refractory adult onset Still’s disease with rituximab

  N. Belfeki, M. Smiti Khanfir, F. Said, A. Hamzaoui, T. Ben Salem, I. Ben Ghorbel, M. Lamloum, M.H. Houman

  159-162

  16-12-2016

  Published: 16 December 2016

  1972

  PDF: 1137
• 

  The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature

  S. Barsotti, E. Cioffi, A. Tripoli, A. Tavoni, A. d’Ascanio, M. Mosca, R. Neri

  78-84

  06-07-2018

  Published: 6 July 2018

  2356

  PDF: 1228
• 

  Are biological drugs safe in pregnancy?

  A. Calligaro, A. Hoxha, A. Ruffatti, L. Punzi

  304-317

  31-03-2015

  Published: 31 March 2015

  3443

  PDF: 2309
• 

  Severe bullous systemic lupus erythematosus successfully treated with low dose rituximab: a case report from sub-Saharan Africa

  A.A. Akpabio, B.I. Otike-Odibi

  115-119

  23-07-2020

  Published: 23 July 2020

  882

  PDF: 571
• 

  Acquired hemophilia A treated with rituximab in a 62-year-old female with rheumatoid arthritis: a case-based review

  D. Mohamadzadeh, S. Assar, F. Farsad

  19-12-2023

  Published: 19 December 2023

  904

  PDF: 251
• 

  Eosinophilic granulomatosis with polyangiitis: sequential use of mepolizumab following rituximab for inadequate asthma control despite vasculitis remission

  B. Cremonezi Lammoglia, L. de Aguiar Trevise, T. Paslar Leal, M. Pereira Lopes Vieira Pinto, G. Hasselmann, N. Salles Rosa Neto

  19-12-2023

  Published: 19 December 2023

  1102

  PDF: 321

• Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab)

  V. Bruzzese, J. Pepe

  306-308

  Published:

  917

  PDF: 744
• 

  Polymyositis following varicella and mumps infection in adults: report of two cases

  F. Masini, K. Gjeloshi, E. Pinotti, R. Ferrara, C. Romano, G. Cuomo

  19-12-2023

  Published: 19 December 2023

  864

  PDF: 305
• 

  GISEA: an Italian biological agents registry in rheumatology

  G. Lapadula, G. Ferraccioli, C. Ferri, L. Punzi, F. Trotta

  155-164

  09-11-2011

  Published: 9 November 2011

  1908

  PDF: 1466

• Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis

  M. Fabris, L. Quartuccio, S. Lombardi, M. Benucci, M. Manfredi, M. Saracco, F. Atzeni, P. Morassi, M.A. Cimmino, E. Pontarini, C. Fabro, R. Pellerito, P. Sarzi-Puttini, M. Cutolo, A. Carletto, L.M. Bambara, F. Fischetti, F. Curcio, E. Tonutti, S. De VIta

  253-258

  Published:

  1964

  PDF: 798

• Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFα agents failed are associated with response to rituximab in rheumatoid arthritis

  L. Quartuccio, S. Salvin, M. Saracco, S. Lombardi, M. Fabris, E. Mansutti, M. Maset, S. Pellerito, S. De Vita

  182-186

  Published:

  961

  PDF: 664
• 

  A short history of anti-rheumatic therapy - VII. Biological agents

  G. Pasero, P. Marson, B. Gatto

  185-194

  09-11-2011

  Published: 9 November 2011

  1286

  PDF: 1190

• Safety of rituximab in rheumatoid arthritis

  M. Covelli, P. Sarzi-Puttini, F. Atzeni, P. Macchioni

  101-106

  Published:

  1586

  PDF: 960
• 

  Anti-N-methyl-d-aspartate receptor encephalitis: mimicker of lupus and multiple sclerosis

  N. Sanghavi, B. Ayesha

  19-12-2023

  Published: 19 December 2023

  1092

  PDF: 286

• B-cell depletion and primary Sjögren’s syndrome: is there a role for rituximab?

  F. Atzeni, P. Sarzi-Puttini

  87-88

  Published:

  1142

  PDF: 611